Oric Pharmaceuticals, Inc. (ORIC) stock intrinsic value fair value estimate & owner earnings analysis

ORIC Pharmaceuticals is a clinical-stage cancer drug developer with no approved products and no product revenue. Its two remaining programs are rinzimetostat, a PRC2 inhibitor being developed for metastatic castration-resistant prostate cancer, which is entering a global Phase 3 registrational trial in the first half of 2026, and enozertinib, a brain-penetrant EGFR inhibitor for non-small cell lung cancer with an EGFR exon 20 mutation, currently in Phase 1b testing. In August 2025 the company narrowed its focus to these two programs and reduced its workforce, having previously funded a broader set of earlier-stage research efforts. Because neither program has regulatory approval, and the company has no signed licensing or commercial agreement that would produce revenue, we have not credited any future product revenue in any of the three cases below. This is a deliberate choice: crediting revenue from a drug that has not yet been approved would mean valuing a hoped-for outcome rather than the business as it exists today. As a result, all of the value in this analysis comes from a single, verifiable fact: the company held approximately $392 million in cash and investments at the end of 2025, has no debt, and is spending that cash down to fund its trials. Base case: cash spending continues at roughly the pace seen recently — about $131 million in 2025, stepping up toward $140–150 million a year as the Phase 3 trial for rinzimetostat ramps up, consistent with results reported for the first half of 2026. At that pace, the company's own disclosed cash position funds operations into 2028. Beyond that point we assign no further value, because nothing yet supports either program generating revenue, and no additional financing is assumed. Bear case: spending runs hotter than currently guided — this company's own operating cash outflow jumped by roughly 31% in a single year as recently as 2024 as its trials advanced — and/or a second round of cost-cutting becomes necessary, similar to what happened in August 2025. Cash is exhausted roughly a year sooner, and modest wind-down costs (severance, lease exit costs) are assumed to consume what little would otherwise remain. Bull case: the cost discipline shown in the 2025 restructuring holds better than the recent trend suggests, keeping annual spending closer to 2025's level and stretching the funded runway modestly longer than currently guided. Because none of the three cases credit any revenue from an eventual drug approval, the range between the bear, base and bull outcomes above is narrow — nearly all of it reflects only how quickly a known cash balance is spent, discounted for time. This is not the same question as whether the shares are a good investment on hope for clinical success; it is deliberately not that question, because that outcome cannot yet be evidenced from the filings. Two accounting judgments materially shaped the result. First, stock-based compensation, which is added back in the reported cash flow statement, is treated here as a real, recurring cost and subtracted. Second, because the company has never had product revenue, we did not try to split its modest equipment spending into "growth" versus "maintenance" categories; all of it was treated as necessary to keep operations running. A one-time, $19.8 million non-cash stock payment used in 2020 to license the enozertinib program was excluded from the years used to set the current baseline, since it does not recur and would otherwise flatter that year's figures. One more factor worth noting: the number of shares outstanding has grown quickly — the average diluted share count is up roughly 23% between full-year 2025 and the second quarter of 2026 — as the company continues to issue new stock to fund its losses. The share count used in this valuation reflects this more recent, larger figure, and further issuance of this kind is likely to continue diluting existing holders as long as the company remains unprofitable. What would make this analysis too conservative: if either rinzimetostat or enozertinib produces clinical data that supports an eventual approval, the shares would likely be worth substantially more than shown here, since none of that potential is included in these figures. Given how much of the eventual outcome depends on trial results that cannot yet be evidenced, the margin-of-safety price is set at a meaningful discount to even the base case.